Literature DB >> 33080353

Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide.

Lucas Guillo1, Christian Rabaud2, Ernest H Choy3, Ferdinando D'Amico4, Silvio Danese5, Siew C Ng6, Laurent Peyrin-Biroulet7.   

Abstract

Herpes zoster is a painful dermatomal cutaneous eruption resulting from reactivation of the latent varicella-zoster virus. Patients with inflammatory bowel diseases have an increased risk of shingles compared with the general population and this risk can be increased with the use of immunosuppressive therapy. Live zoster vaccine and recombinant zoster vaccine have shown efficacy for the prevention of herpes zoster. The recombinant zoster vaccine seems to offer greater efficacy and long-term protection profile compared with the life zoster vaccine. However, their use in clinical practice still is unclear and updated vaccination recommendations are lacking. This review discusses the risk for shingles in patients with inflammatory bowel diseases, available vaccines, and their efficacy and safety profiles. We also provide guidance on who, when, and how to vaccinate for herpes zoster in routine clinical practice among patients with inflammatory bowel diseases.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Herpes Zoster; Herpes Zoster Vaccine; Inflammatory Bowel Diseases; Shingles; Shingrix; Zostavax

Mesh:

Substances:

Year:  2020        PMID: 33080353     DOI: 10.1016/j.cgh.2020.10.027

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  3 in total

Review 1.  Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.

Authors:  Ferdinando D'Amico; Fernando Magro; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

2.  A knowledge gap unmasked: viral transmission in surgical smoke: a systematic review.

Authors:  Connal Robertson-More; Ted Wu
Journal:  Surg Endosc       Date:  2021-01-25       Impact factor: 4.584

Review 3.  Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.

Authors:  Maria Napolitano; Ferdinando D'Amico; Elisa Ragaini; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Drug Des Devel Ther       Date:  2022-06-17       Impact factor: 4.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.